← back to search

Dirk Jan A. R. Moes

Maastricht University · NL
Area of research
Transplantation · Pharmacology
Research interest
Research interests include Renal Transplantation Outcomes and Treatments, Pharmacogenetics and Drug Metabolism, COVID-19 Clinical Research Studies, and Hematopoietic Stem Cell Transplantation.
h-index
31
citations
4,131
works
161
NIH funding
primary concept
Medicine
email

Recent publications

Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
Therapeutic Drug Monitoring 2024cited by 24position: middledoi
Everolimus Personalized Therapy: Second Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
Therapeutic Drug Monitoring 2024cited by 12position: middledoi
Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology – an analysis of the closed cohorts of a multicentre prospective study
British Journal of Cancer 2024cited by 10position: middledoi
Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn’s Disease
Digestive Diseases and Sciences 2023cited by 21position: middledoi
Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study
Annals of Oncology 2022cited by 73position: middledoi
Therapeutic Drug Monitoring and Dosage Adjustments of Immunosuppressive Drugs When Combined With Nirmatrelvir/Ritonavir in Patients With COVID-19
Therapeutic Drug Monitoring 2022cited by 56position: middledoi
Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
Therapeutic Drug Monitoring 2021cited by 196position: middledoi
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report
Therapeutic Drug Monitoring 2019cited by 639position: middledoi
Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab
Clinical Pharmacokinetics 2019cited by 126position: middledoi
Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study
Journal of Clinical Oncology 2019cited by 89position: middledoi
Therapeutic Drug Monitoring of Oral Anticancer Drugs: The Dutch Pharmacology Oncology Group–Therapeutic Drug Monitoring Protocol for a Prospective Study
Therapeutic Drug Monitoring 2019cited by 48position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Hans Gelderblom · University Medical Center4 papers (2019–2024)Stijn L.W. Koolen · Erasmus MC3 papers (2019–2024)Ruben A.G. van Eerden · Erasmus MC Cancer Institute3 papers (2019–2024)Ron H.J. Mathijssen · Erasmus University Rotterdam3 papers (2019–2024)Alwin D. R. Huitema · University of Applied Sciences Utrecht3 papers (2019–2024)Nielka P. van Erp · University Medical Center3 papers (2019–2024)Ingrid M.E. Desar · Netherlands Comprehensive Cancer Organisation3 papers (2019–2024)Stefanie L. Groenland · The Netherlands Cancer Institute3 papers (2019–2024)Marinda Meertens · The Netherlands Cancer Institute2 papers (2022–2024) · 2 papers (2019–2023)Alex L.T. Imholz · Deventer Ziekenhuis2 papers (2022–2024)Kim Westerdijk · University Medical Center2 papers (2022–2024)Annelie Vulink · Reinier de Graaf Hospital2 papers (2022–2024)Annick de Vries · Medizinische Hochschule Hannover1 papers (2024–2024) · 1 papers (2024–2024)Klemens Budde · Humboldt-Universität zu Berlin1 papers (2022–2022)Ron J. Keizer · International Neuromodulation Society1 papers (2024–2024) · 1 papers (2022–2022)Jos H. Beijnen · University of Applied Sciences Utrecht1 papers (2022–2022) · 1 papers (2022–2022)